Leerink Partners Begins Coverage on Elanco Animal Health (NYSE:ELAN)
Equities research analysts at Leerink Partners assumed coverage on shares of Elanco Animal Health (NYSE:ELAN – Get Free ...
Zoetis (NYSE:ZTS) Coverage Initiated by Analysts at Leerink Partners
Investment analysts at Leerink Partners began coverage on shares of Zoetis (NYSE:ZTS – Get Free Report) in a note issued to ...
Fintel on MSN2d
Leerink Partners Initiates Coverage of Zoetis (ZTS) with Outperform Recommendation
Fintel reports that on December 2, 2024, Leerink Partners initiated coverage of Zoetis (NYSE:ZTS) with a Outperform ...
Fintel on MSN2d
Leerink Partners Initiates Coverage of IDEXX Laboratories (IDXX) with Outperform Recommendation
Fintel reports that on December 2, 2024, Leerink Partners initiated coverage of IDEXX Laboratories (NasdaqGS:IDXX) with a ...
bovnews1d
Why Did Leerink Partners Give Zoetis Inc (ZTS) Stock Outperform Rating?
On Monday, Zoetis Inc (ZTS) stock saw a modest uptick, ending the day at $176.81 which represents a slight increase of $1.56 or 0.89% from the prior close of $175.25. The stock opened at $175.78 and ...
BioSpace14h
Amylin Commands Weight Loss Attention as Industry Anticipates Novo’s Phase III CagriSema Readout
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...
Zepbound tops Wegovy for weight loss in Eli Lilly study
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...
AbbVie gains on Leerink Partners upgrade to Outperform
AbbVie (ABBV) shares jump after Leerink Partners upgraded the stock to Outperform, saying the recent sell-off creates an ...
Check Out What Whales Are Doing With ABBV
Our analysis of options history for AbbVie ABBV revealed 13 unusual trades. Delving into the details, we found 46% of traders ...
Zacks.com on MSN9d
AbbVie Stock Rises After Leerink Partners Upgrades Its Rating
AbbVie shares rose after a Leerink Partners analyst upgraded the stock's rating to outperform. The improved rating comes ...
Leerink Partners Keeps Their Buy Rating on Insulet (PODD)
Leerink Partners analyst Mike Kratky maintained a Buy rating on Insulet (PODD – Research Report) on November 25 and set a price target of ...
Exelixis’s Cabozantinib Studies Face Uncertainty and Safety Concerns Leading to Hold Rating
Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating on November 29.Don't Miss our ...